Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsSulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysisBromocriptine for type 2 diabetes mellitusSHRINE: enabling nationally scalable multi-site disease studiesEffect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesThe Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical TrialsPlace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesShould antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Metformin in obesity, cancer and aging: addressing controversiesRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolRepresentativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD)HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitusUnderstanding and overcoming metformin gastrointestinal intolerance.Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.AMPK activation--protean potential for boosting healthspan.Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research DatabaseIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisSelective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort studyA randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Metformin in cancer prevention and therapy.Defining and achieving treatment success in patients with type 2 diabetes mellitusSulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulinComparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort studyOverview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study.Time to be cautious about prescribing sulfonylureas?A hospital-based observational study of type 2 diabetic subjects from Gujarat, India.Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitusEffects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones.Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
P2860
Q21144611-A575DBDF-EEFE-45C6-AEB3-FEE152C34E94Q22241119-21FB5EFD-4C37-41C4-80B5-CD7FE0E6FDDBQ24201924-12C8D99C-94A0-4189-AFE1-3BE4AEDB90FFQ24288701-312C41D9-0863-49AD-8A4A-9900CAEE264CQ24628988-04E32FE3-712D-4E8E-AF51-3F1EEBC880EFQ24632655-9B51297E-AD99-4B40-BBD4-30BDF51D0564Q26748870-AC148C2E-E3BD-4926-9911-B9812AD376D5Q26783199-9608DD30-B790-4DDF-B4BF-12A0D60C3B09Q26999933-F4A9A8EC-0BA2-4022-84B9-9F8018AA84C5Q27022813-9C2570AA-F0FA-41BE-B621-56221D54FD6EQ27024799-376190BD-C2AE-4145-AE82-923FA94A05DCQ27692665-3B645975-7281-404F-B98D-E25B3AC18FD8Q28480735-56B0E5CE-44FA-46C0-8358-7921B01490A9Q28551188-F0C0DBEC-CD16-42F9-8704-4F8CEB23838FQ28680747-4891D0E3-54F7-4796-8F59-5CB97260B68AQ28728521-CD946E97-5043-42C5-A589-896EC0327A65Q30240030-D4A474AC-52CD-4BB6-A281-5478A953F4F9Q31095975-B37FD51D-7E42-4B57-95B2-73A2EAAC98F2Q33558075-EC0596E1-F1F7-48F1-BF1E-D4763D3631A3Q33689169-1504CCC4-90E9-40AA-A3A4-63CD4CE2AE1AQ33873040-3B1C68B1-42AF-4558-8F32-14C183BCFE5BQ33880174-11723E2E-96F2-491E-B59E-A49AA58E35C3Q33976093-88226B3A-D920-4F82-A690-250340C6E13DQ34099031-58A9F771-EC63-4C3D-B1FB-672178369565Q34158078-1E58D1D6-7815-4CCE-A63C-46F910882F4BQ34178322-65FA2A18-9868-4952-A9D5-7CF592AC1FE2Q34315432-B0994680-6954-4A1C-B8BF-65E667A277ACQ34357983-B6E4F9A3-49DC-4629-9A2C-9B23F752152CQ34374314-B364E6A7-C9DC-4E49-885C-F77CBC346F8FQ34392375-9EBE7A71-AB7C-4E7C-876E-6B4FCECD6A8EQ34541875-41A61B86-B627-43B4-8A03-ABB13D0D2C44Q34620604-66193368-BEBA-43ED-BC15-940BEBE777ABQ34644993-619D9F20-527A-4427-B55C-C0516420B166Q34783302-6851B121-20D6-4546-B757-AA890D8A554EQ34998627-81DB8781-E1D1-4AEA-A24C-641B974DA7BBQ35076020-8C68BE6F-85CD-4986-9EFE-A1135F4231AAQ35090308-948D2C0B-A88E-4CE8-A8DE-E67C4687762EQ35197212-FDFCD601-D1DA-4F83-87BE-C2494B12FACBQ35228184-D7B55EA3-61F9-4948-9000-63051DD3F38BQ35667116-C93F83DD-6203-4E86-BFB4-D9D0D9AAFC2F
P2860
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk of cardiovascular disease ...... al practice research database.
@en
Risk of cardiovascular disease ...... al practice research database.
@nl
type
label
Risk of cardiovascular disease ...... al practice research database.
@en
Risk of cardiovascular disease ...... al practice research database.
@nl
prefLabel
Risk of cardiovascular disease ...... al practice research database.
@en
Risk of cardiovascular disease ...... al practice research database.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Risk of cardiovascular disease ...... ral practice research database
@en
P2093
Mariam Molokhia
Martin R Wilkins
Robert I Hughes
P2860
P356
10.1136/BMJ.B4731
P407
P577
2009-12-03T00:00:00Z